vorinostat has been researched along with Chronic Disease in 3 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Increasing numbers of patients are presenting with relapsed/refractory multiple myeloma (MM) following treatment with bortezomib." | 7.76 | Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice. ( Jagannath, S; Mazumder, A; Vesole, DH, 2010) |
| " At the end of dosing schedule, neurobehavioral tests were conducted; followed by mechanistic evaluation through biochemical analysis, RTPCR and western blot in serum and hippocampus." | 5.48 | Antidepressant activity of vorinostat is associated with amelioration of oxidative stress and inflammation in a corticosterone-induced chronic stress model in mice. ( Js, IC; Kv, A; Lahkar, M; Madhana, RM; Naidu, VGM; Sinha, S, 2018) |
| "Increasing numbers of patients are presenting with relapsed/refractory multiple myeloma (MM) following treatment with bortezomib." | 3.76 | Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice. ( Jagannath, S; Mazumder, A; Vesole, DH, 2010) |
| " At the end of dosing schedule, neurobehavioral tests were conducted; followed by mechanistic evaluation through biochemical analysis, RTPCR and western blot in serum and hippocampus." | 1.48 | Antidepressant activity of vorinostat is associated with amelioration of oxidative stress and inflammation in a corticosterone-induced chronic stress model in mice. ( Js, IC; Kv, A; Lahkar, M; Madhana, RM; Naidu, VGM; Sinha, S, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kv, A | 1 |
| Madhana, RM | 1 |
| Js, IC | 1 |
| Lahkar, M | 1 |
| Sinha, S | 1 |
| Naidu, VGM | 1 |
| McNeil, C | 1 |
| Mazumder, A | 1 |
| Vesole, DH | 1 |
| Jagannath, S | 1 |
3 other studies available for vorinostat and Chronic Disease
| Article | Year |
|---|---|
Antidepressant activity of vorinostat is associated with amelioration of oxidative stress and inflammation in a corticosterone-induced chronic stress model in mice.
Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Antioxidants; Anxiety; Chronic Disease; Co | 2018 |
Preventing graft-versus-host disease: transplanters glimpse hope beyond immunosuppressants.
Topics: Acute Disease; Bone Marrow Transplantation; Boronic Acids; Bortezomib; Chronic Disease; Clinical Tri | 2013 |
Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Chronic Disease; Clinical Trials as Topic; Disease | 2010 |